UBE2N as a novel prognostic and therapeutic biomarker of lung adenocarcinoma
UBE2N may serve as a promising prognostic biomarker and therapeutic target for LUAD. Inhibition of UBE2N is expected to suppress LUAD progression and enhance therapeutic efficacy.
Authors
- Chunzhen Li (ORCID: https://orcid.org/0009-0005-6462-6840)
- Yanqin Wu (ORCID: https://orcid.org/0000-0003-0511-0893)
- Jennifer Zhang
- Shulei Yin
- Tiejun Zhao (ORCID: https://orcid.org/0000-0003-3624-9783)
- Haofeng Yin
- Chen Wang (ORCID: https://orcid.org/0009-0004-3799-4579)
- Yibo Xue
- Yuchen Guo
Institutions
- Naval Medical Research Command (US)
- Second Military Medical University (CN)
- Shanghai Changzheng Hospital (CN)
- Changhai Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-08-11
- DOI
- https://doi.org/10.3389/fimmu.2025.1636503
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00